730 related articles for article (PubMed ID: 21610146)
1. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
Moon EK; Carpenito C; Sun J; Wang LC; Kapoor V; Predina J; Powell DJ; Riley JL; June CH; Albelda SM
Clin Cancer Res; 2011 Jul; 17(14):4719-30. PubMed ID: 21610146
[TBL] [Abstract][Full Text] [Related]
2. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
Front Immunol; 2021; 12():628906. PubMed ID: 33777013
[TBL] [Abstract][Full Text] [Related]
3. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M
Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643
[TBL] [Abstract][Full Text] [Related]
4. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
Moon EK; Wang LC; Dolfi DV; Wilson CB; Ranganathan R; Sun J; Kapoor V; Scholler J; Puré E; Milone MC; June CH; Riley JL; Wherry EJ; Albelda SM
Clin Cancer Res; 2014 Aug; 20(16):4262-73. PubMed ID: 24919573
[TBL] [Abstract][Full Text] [Related]
5. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.
Craddock JA; Lu A; Bear A; Pule M; Brenner MK; Rooney CM; Foster AE
J Immunother; 2010 Oct; 33(8):780-8. PubMed ID: 20842059
[TBL] [Abstract][Full Text] [Related]
6. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
Klampatsa A; Achkova DY; Davies DM; Parente-Pereira AC; Woodman N; Rosekilly J; Osborne G; Thayaparan T; Bille A; Sheaf M; Spicer JF; King J; Maher J
Cancer Lett; 2017 May; 393():52-59. PubMed ID: 28223167
[TBL] [Abstract][Full Text] [Related]
7. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
Lanitis E; Poussin M; Hagemann IS; Coukos G; Sandaltzopoulos R; Scholler N; Powell DJ
Mol Ther; 2012 Mar; 20(3):633-43. PubMed ID: 22127019
[TBL] [Abstract][Full Text] [Related]
8. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.
Asai H; Fujiwara H; An J; Ochi T; Miyazaki Y; Nagai K; Okamoto S; Mineno J; Kuzushima K; Shiku H; Inoue H; Yasukawa M
PLoS One; 2013; 8(2):e56820. PubMed ID: 23441216
[TBL] [Abstract][Full Text] [Related]
9. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
Schuberth PC; Hagedorn C; Jensen SM; Gulati P; van den Broek M; Mischo A; Soltermann A; Jüngel A; Marroquin Belaunzaran O; Stahel R; Renner C; Petrausch U
J Transl Med; 2013 Aug; 11():187. PubMed ID: 23937772
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Haas AR; Tanyi JL; O'Hara MH; Gladney WL; Lacey SF; Torigian DA; Soulen MC; Tian L; McGarvey M; Nelson AM; Farabaugh CS; Moon E; Levine BL; Melenhorst JJ; Plesa G; June CH; Albelda SM; Beatty GL
Mol Ther; 2019 Nov; 27(11):1919-1929. PubMed ID: 31420241
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
[TBL] [Abstract][Full Text] [Related]
12. Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability.
Hu JF; Wang ZW; Liao CY; Chen ZW; Kang FP; Lin CF; Lin TS; Huang L; Tian YF; Chen S
Front Immunol; 2022; 13():958960. PubMed ID: 35990619
[TBL] [Abstract][Full Text] [Related]
13. Mesothelin, a novel immunotherapy target for triple negative breast cancer.
Tchou J; Wang LC; Selven B; Zhang H; Conejo-Garcia J; Borghaei H; Kalos M; Vondeheide RH; Albelda SM; June CH; Zhang PJ
Breast Cancer Res Treat; 2012 Jun; 133(2):799-804. PubMed ID: 22418702
[TBL] [Abstract][Full Text] [Related]
14. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
Zhao Y; Moon E; Carpenito C; Paulos CM; Liu X; Brennan AL; Chew A; Carroll RG; Scholler J; Levine BL; Albelda SM; June CH
Cancer Res; 2010 Nov; 70(22):9053-61. PubMed ID: 20926399
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy.
Quach HT; Skovgard MS; Villena-Vargas J; Bellis RY; Chintala NK; Amador-Molina A; Bai Y; Banerjee S; Saini J; Xiong Y; Vista WR; Byun AJ; De Biasi A; Zeltsman M; Mayor M; Morello A; Mittal V; Gomez DR; Rimner A; Jones DR; Adusumilli PS
Cancer Immunol Res; 2023 Oct; 11(10):1314-1331. PubMed ID: 37540803
[TBL] [Abstract][Full Text] [Related]
16. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects.
Zhu Y; Wang K; Yue L; Zuo D; Sheng J; Lan S; Zhao Z; Dong S; Hu S; Chen X; Feng M
Pharmacol Res; 2024 May; 203():107186. PubMed ID: 38641176
[TBL] [Abstract][Full Text] [Related]
17. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.
Maus MV; Haas AR; Beatty GL; Albelda SM; Levine BL; Liu X; Zhao Y; Kalos M; June CH
Cancer Immunol Res; 2013 Jul; 1(1):26-31. PubMed ID: 24777247
[TBL] [Abstract][Full Text] [Related]
18. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
Gulati P; Rühl J; Kannan A; Pircher M; Schuberth P; Nytko KJ; Pruschy M; Sulser S; Haefner M; Jensen S; Soltermann A; Jungraithmayr W; Eisenring M; Winder T; Samaras P; Tabor A; Stenger R; Stupp R; Weder W; Renner C; Münz C; Petrausch U
Clin Cancer Res; 2018 Aug; 24(16):3981-3993. PubMed ID: 29748183
[No Abstract] [Full Text] [Related]
19. Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.
Riese MJ; Wang LC; Moon EK; Joshi RP; Ranganathan A; June CH; Koretzky GA; Albelda SM
Cancer Res; 2013 Jun; 73(12):3566-77. PubMed ID: 23576561
[TBL] [Abstract][Full Text] [Related]
20. A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial.
Mayor M; Zeltsman M; McGee E; Adusumilli PS
Immunotherapy; 2016 May; 8(5):491-4. PubMed ID: 27140404
[No Abstract] [Full Text] [Related]
[Next] [New Search]
